GlycoMimetics Receives $15-Million Payment From Pfizer
GlycoMimetics, Inc. recently announced that Pfizer has made a $15-million payment to GlycoMimetics under the terms of the parties’ collaboration for the development of rivipansel (GMI-1070). Under the collaboration, Pfizer plans to initiate a Phase III clinical trial of rivipansel, which will trigger an additional $20-million milestone payment to GlycoMimetics upon the dosing of the first patient in the trial.
“Moving into Phase III will be a significant step forward in our effort to potentially address the unmet needs of individuals with sickle cell disease. With the commitment of our collaborator, Pfizer, we hope this will enable us to bring to patients, caregivers, and physicians an important new medication for treatment of vaso-occlusive crisis or VOC of sickle cell disease,” said Rachel King , Chief Executive Officer, GlycoMimetics.
GlycoMimetics entered into a collaboration and exclusive license agreement with Pfizer for rivipansel in October 2011. The companies are currently developing rivipansel as a potential treatment for VOC of sickle cell disease. GlycoMimetics conducted a Phase II randomized, double-blinded study examining the efficacy, safety, and pharmacokinetics of rivipansel in hospitalized sickle cell disease patients experiencing VOC. GlycoMimetics reported top line data from the trial in April 2013 and presented full data from the clinical trial in two oral presentations and one poster presentation at the December 2013 meeting of the American Society of Hematology (ASH.) One of the oral presentations was selected as Best of ASH.
In the Phase II trial, patients treated with rivipansel experienced reductions in time to reach resolution of VOC, length of hospital stay, and use of opioid analgesics for pain management, in each case as compared to patients receiving placebo.
Vaso-occlusive crisis of sickle cell (VOC) is a condition that represents a significant unmet medical need. Sickle cell disease is one of the most prevalent genetic disorders in the US, affecting over 90,000 people. It is a chronic condition causing substantial illness and death.
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. For more information, visit www.glycomimetics.com.
Total Page Views: 907
